CN110234656B - 外核苷酸酶抑制剂及其使用方法 - Google Patents

外核苷酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN110234656B
CN110234656B CN201780068695.9A CN201780068695A CN110234656B CN 110234656 B CN110234656 B CN 110234656B CN 201780068695 A CN201780068695 A CN 201780068695A CN 110234656 B CN110234656 B CN 110234656B
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780068695.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110234656A (zh
Inventor
陈丽晶
J.李
E.B.修格连
R.J.比勒多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deqi Medical Co ltd
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CN110234656A publication Critical patent/CN110234656A/zh
Application granted granted Critical
Publication of CN110234656B publication Critical patent/CN110234656B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780068695.9A 2016-09-09 2017-09-08 外核苷酸酶抑制剂及其使用方法 Active CN110234656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662385730P 2016-09-09 2016-09-09
US62/385730 2016-09-09
PCT/US2017/050659 WO2018049145A1 (en) 2016-09-09 2017-09-08 Ectonucleotidase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN110234656A CN110234656A (zh) 2019-09-13
CN110234656B true CN110234656B (zh) 2023-02-28

Family

ID=61559594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068695.9A Active CN110234656B (zh) 2016-09-09 2017-09-08 外核苷酸酶抑制剂及其使用方法

Country Status (6)

Country Link
US (2) US10472364B2 (OSRAM)
EP (1) EP3510040A4 (OSRAM)
JP (1) JP7125144B2 (OSRAM)
CN (1) CN110234656B (OSRAM)
TW (1) TWI767937B (OSRAM)
WO (1) WO2018049145A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3510040A4 (en) * 2016-09-09 2020-06-03 Calithera Biosciences, Inc. ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
AU2017382888B2 (en) * 2016-12-22 2021-12-23 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2018209324A2 (en) * 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
JP7538047B2 (ja) * 2018-06-21 2024-08-21 アンテンジーン セラピューティクス リミテッド エクトヌクレオチダーゼ阻害剤及びその使用方法
EP3843742A4 (en) * 2018-08-28 2022-04-20 Jiangsu Hengrui Medicine Co., Ltd. CD73 INHIBITORS AND THEIR THERAPEUTIC USES
EP3849992A4 (en) 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
WO2020081690A1 (en) * 2018-10-17 2020-04-23 Xibin Liao 6-mercaptopurine nucleoside analogues
EP3939988A4 (en) * 2019-03-20 2022-08-24 Korea Research Institute of Chemical Technology Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient
CN113905743B (zh) * 2019-03-29 2024-04-16 江苏恒瑞医药股份有限公司 Cd73抑制剂及其治疗用途
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
CA3143496A1 (en) * 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
SI4051688T1 (sl) 2019-10-30 2025-08-29 Oric Pharmaceuticals, Inc. Inhibitorji CD73
EP4212524A4 (en) * 2020-09-08 2024-08-28 Betta Pharmaceuticals Co., Ltd Cd73 inhibitor and application thereof in medicine
CN114099698B (zh) * 2021-11-26 2024-02-09 山东大学齐鲁医院 一种pH敏感脂质体及其制备方法与应用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN117430651A (zh) * 2022-07-21 2024-01-23 武汉精准智药科技有限公司 单磷酸核苷类化合物及其制备方法
CN115611954A (zh) * 2022-12-19 2023-01-17 天津奥瑞芙生物医药有限公司 一种5′-o-(4,4′-二甲氧基三苯甲基)-核苷的制备方法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
KR960008669B1 (ko) 1991-04-24 1996-06-28 야마사 쇼오유 가부시끼가이샤 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
WO1994010128A1 (en) 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5635608A (en) 1994-11-08 1997-06-03 Molecular Probes, Inc. α-carboxy caged compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
NL1005244C2 (nl) 1997-02-10 1998-08-18 Inst Voor Agrotech Onderzoek Oppervlakte-actieve aminen en glycosiden.
DK1348427T3 (da) 1997-07-29 2008-06-30 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004096233A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
JP5225991B2 (ja) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク チアゾロ［４，５−ｄ］ピリミジンのカーボネート及びカルバメートプロドラッグ
CA2705092A1 (en) 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
JP2013533354A (ja) 2010-07-08 2013-08-22 ライフ テクノロジーズ コーポレーション ｉｎｓｉｔｕ化学発光基質およびアッセイ方法
CN103649069B (zh) 2011-05-03 2016-09-14 生命科技公司 闪光和辉光1,2-二氧杂环丁烷类
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
WO2015200219A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2017024310A1 (en) 2015-08-06 2017-02-09 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
DK3362461T3 (da) 2015-10-16 2022-05-09 Modernatx Inc Mrna-cap-analoger med modificeret phosphatbinding
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
EA038565B1 (ru) 2016-01-08 2021-09-15 Аркус Байосайенсиз, Инк. Модуляторы экто-5'-нуклеотидазы и их применение
EP3510040A4 (en) * 2016-09-09 2020-06-03 Calithera Biosciences, Inc. ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
AU2017382888B2 (en) 2016-12-22 2021-12-23 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164573A1 (en) * 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Design and Synthesis of α-Carboxy Phosphononucleosides;Sebastien Debarge，等;《J. Org. Chem.》;20101201;第76卷;第105-126页 *
Discovery and development of clofarabine: a nucleoside analogue for treating cancer;Peter L. Bonate，等;《NATURE REVIEWS: DRUG DISCOVERY 》;20061031;第5卷;第855-863页 *
Isabelle Hladezuk，等.Development of O-H insertion for the attachment of phosphonates to nucleosides *
RN：1260067-82-0、1260067-78-4、1259875-56-3;Chemical Abstract;《STN-Registry》;20110120 *
synthesis of α-carboxy phosphononucleosides.《Tetrahedron》.2012,第68卷第1894-1909页. *

Also Published As

Publication number Publication date
TW201811775A (zh) 2018-04-01
CN110234656A (zh) 2019-09-13
WO2018049145A1 (en) 2018-03-15
JP7125144B2 (ja) 2022-08-24
TWI767937B (zh) 2022-06-21
US20200087310A1 (en) 2020-03-19
JP2019530669A (ja) 2019-10-24
EP3510040A1 (en) 2019-07-17
US11208414B2 (en) 2021-12-28
EP3510040A4 (en) 2020-06-03
US10472364B2 (en) 2019-11-12
US20180072742A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
CN110234656B (zh) 外核苷酸酶抑制剂及其使用方法
US11034715B2 (en) Ectonucleotidase inhibitors and methods of use thereof
JP7538047B2 (ja) エクトヌクレオチダーゼ阻害剤及びその使用方法
JP2022537358A (ja) エクトヌクレオチダーゼ阻害剤およびその使用方法
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof
HK40013556A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40017040A (en) Ectonucleotidase inhibitors and methods of use thereof
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013556

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230412

Address after: Kowloon, Hongkong, China

Patentee after: Deqi Medical Co.,Ltd.

Address before: California, USA

Patentee before: CALITHERA BIOSCIENCES, Inc.